Clin2
NCT06056102Possibly a fitRecruiting

CAR-T cell therapy to help highly sensitized kidney transplant patients

Kidney TransplantKidney FailureEnd Stage Renal Failure on Dialysis

Treatments studied

Part of Kidney & urinary, Women’s health & pregnancy clinical trials.

This trial tests whether a special immune cell treatment (CAR-T cells) can lower the antibodies that make it very hard for you to receive a kidney transplant. If it works, you might become eligible for a transplant sooner.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
20 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You are between 18 and 65 years old and have kidney failure requiring dialysis.
  • You have a very high level of sensitization (cPRA of 99.5% or higher) and have been on the kidney transplant waiting list for at least a year.
  • Your blood type is O or B, and you do not have a living donor or haven't been matched in a kidney swap program for 12 months.
  • You are willing to stay within 2 hours of the study site for 28 days after the CAR-T cell infusion.
  • You have had certain vaccines and test negative for tuberculosis, and you are not pregnant or breastfeeding.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06809075Recruiting
Stem cell therapy to help highly sensitized patients get a kidney transplant

This trial tests if a special stem cell treatment (using your own stem cells) can reset your immune system so you can accept a kidney from a deceased donor, even if you have very high antibody levels that make it hard to find a match. It's for people who have been waiting a long time and haven't had a transplant offer.

Barcelona
NCT07350837Recruiting· Early Phase 1
CAR-T therapy for highly sensitized kidney transplant patients

This trial tests a new CAR-T therapy that targets immune cells to reduce harmful antibodies in highly sensitized kidney transplant candidates. The goal is to help your body accept a kidney from a donor that would otherwise be rejected.

Wuhan, Hubei
NCT07241468Recruiting· Early Phase 1
CAR-T cell therapy for immune kidney disease

This trial tests a special cell treatment (CAR-T) for people with immune-related kidney disease that has not responded to standard therapy. The treatment aims to remove faulty immune cells that damage the kidneys.

Shanghai
NCT06681337Not yet recruiting· Early Phase 1
CAR-T cell therapy for stubborn lupus kidney disease

This early-phase trial tests a special immune cell therapy (CAR-T) for people with lupus nephritis that has not improved with standard treatments. The therapy uses your own modified cells to target and calm the overactive immune system causing kidney damage.

NCT06553898Recruiting· Phase 1
CAR-T cell therapy for hard-to-treat kidney disease

This trial tests a new CAR-T cell treatment for children and adults with steroid-resistant nephrotic syndrome (SRNS), a kidney condition that doesn't get better with standard medicines. The goal is to see if this therapy can help improve kidney function when other treatments have failed.

Hangzhou, Zhejiang
NCT07607197Recruiting· Phase 1/Phase 2
Immune Reset to Help Highly Sensitized Kidney Transplant Patients

This study tests whether a special immune-resetting treatment can help patients who have developed too many antibodies against donor kidneys get access to a compatible kidney transplant. The treatment uses chemotherapy and stem cell transplantation to 'reset' your immune system so it stops rejecting potential donor kidneys.

Barcelona, Catalonia

Hear when a new Kidney Transplant trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.